Oak GLP-1 Review - 2026 Updated: Current Pricing, FDA Enforcement Status, and What Patients Are Asking Right Now

LOS ANGELES, April 28, 2026 (Newswire.com) - Disclosure: This is a sponsored advertorial. This article contains affiliate links - if you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented. This article is for informational purposes only and does not constitute medical advice, a diagnosis, a treatment recommendation, or a guarantee of prescription approval, medication availability, safety, weight loss, or any clinical outcome. Prescription decisions are made exclusively by licensed clinicians. Compounded medications are not FDA-approved finished drug products. Nothing in this article is intended to encourage any unauthorized use of prescription medications. Consult a qualified healthcare professional before starting any prescription treatment program. Any customer experiences referenced by Oak or third-party platforms should not be interpreted as typical results - individual outcomes will vary.

Oak GLP-1 Reviewed: Telehealth Weight Loss Access, Pricing Transparency, and FDA Guidance Explained

The compounded GLP-1 landscape has shifted significantly since early 2025. Patients who are researching Oak Longevity in April 2026 are entering a market where the FDA has issued warning letters to 30 telehealth companies, where pharmacy supply chains have narrowed under enforcement pressure, and where the pricing and program availability that existed twelve months ago may look different today. This overview was written specifically for that environment - not as a promotional piece, but as the kind of informed, current breakdown that helps readers ask the right questions before committing to any program, including this one.

If you landed here because you searched "Is Oak legit," "Oak GLP-1 pricing," "compounded semaglutide 2026," or something similar - you're in the right place. Many people researching Oak right now are trying to verify three things: whether the platform is operating within current regulatory standards, whether the pricing is real and stable, and whether compounded semaglutide is still a viable option after the FDA's recent enforcement actions. This article addresses all three directly.

This article does not recommend Oak over any other provider. It is intended to give you the factual framework to make that evaluation yourself.

View the current Oak program offer (official Oak page)

What Has Changed in the Compounded GLP-1 Space - and Why It Matters Before You Enroll Anywhere in 2026

This section matters regardless of which platform you're evaluating. The GLP-1 telehealth space that many patients researched in 2024 and early 2025 looks meaningfully different today, and understanding what changed helps you ask smarter questions of any provider - including Oak.

January-February 2026: The FDA formally announced its intent to take enforcement action against non-shortage compounded GLP-1 products. The agency's position: with the semaglutide shortage resolved, the broad legal basis under which many compounders previously operated had significantly narrowed. 503B outsourcing facilities that had been supplying large-scale compounded GLP-1 demand began facing sharply increased scrutiny. Multiple platforms adjusted pricing upward or changed their pharmacy arrangements in response.

March 2026: The FDA issued warning letters to 30 telehealth companies specifically for making false or misleading claims about compounded GLP-1 products. The two primary violations cited: implying that compounded medications were equivalent to FDA-approved products, and obscuring which entity was actually doing the compounding by marketing drugs under the telehealth company's own brand without adequate disclosure. These letters were issued to specific named companies and do not apply universally to all telehealth platforms - but they establish the enforcement standard the FDA is now actively applying across the category.

April 2026 (current): The number of compliant compounding pharmacies still operating in this space at scale is smaller than it was twelve months ago. Platforms that were widely available in 2024 have, in some cases, raised prices, changed their pharmacy partners, or stopped compounding GLP-1s entirely. 503A patient-specific compounding by licensed pharmacies remains a legal pathway under the right conditions. Verifying a platform's current pharmacy partners and those pharmacies' regulatory standing is more important right now than it has ever been.

This timeline is based on publicly available FDA communications and industry reporting. It will be updated as the regulatory picture evolves. It is not legal advice.

What Is Oak Longevity? Understanding Exactly What You're Signing Up For

Oak Longevity Holdings Corp. is a telehealth technology platform - not a healthcare provider. That distinction is not legal fine print. It shapes everything about what Oak can and cannot do for you, and Oak's own Terms of Use state it plainly: "Oak does not provide healthcare services."

Three separate entities are involved every time a patient goes through Oak's process. Understanding what each one does is the single most important thing you can know before submitting an intake form anywhere in this space.

Oak Longevity Holdings Corp. (the platform) - Oak operates the technology: the intake form, payment processing, coordination, and logistics. Per its Terms of Use, Oak does not diagnose, prescribe, or treat. It connects you to clinical services. It is not a provider of those services.

Licensed Medical Providers (independent clinicians) - Oak states it contracts with independent physicians and nurse practitioners in the United States, organized through professional corporations including NVP Medical Group, P.A., operating across multiple states. These clinicians review your health intake and make every clinical decision - including whether to issue a prescription at all. Oak cannot guarantee that any individual will receive a prescription, because that determination belongs entirely to the evaluating clinician based on your specific health information.

Partner Compounding Pharmacies (licensed U.S. pharmacies) - Once a prescription is issued, a licensed compounding pharmacy prepares and ships your medication. These are independent, licensed U.S. pharmacies that dispense based on the prescriptions they receive from the treating providers. They are not Oak.

This three-entity structure - platform, clinician, pharmacy - is standard across the telehealth industry. It ensures clinical decisions remain with licensed clinicians, not with the technology company. It also means that if you have questions about your medication, your prescription, or your clinical care, those questions go to the clinician or pharmacy - not to Oak's customer service team.

This program is not designed for emergency care, rapid medical intervention, or unmanaged complex conditions requiring close in-person evaluation.

Compounded GLP-1 Medications: What They Are, What They Are Not, and What the FDA Has Said

This is the section that most GLP-1 platform ads skip entirely. Read it before you read anything else about pricing or process.

Compounded semaglutide and tirzepatide are not Ozempic, Wegovy, Mounjaro, or Zepbound. They may be prepared using an active pharmaceutical ingredient intended to correspond to the active ingredient in those FDA-approved medications - but compounded medications are not FDA-approved finished drug products. They have not been reviewed by the FDA for safety, effectiveness, or quality before being dispensed. This is not a technicality. It is a fundamental regulatory and clinical distinction.

Here is what Oak's own FAQ states on this point, attributed directly: "Compounded medications contain the same active ingredient as their brand-name counterparts. The core therapeutic molecule is identical. The difference is that compounded medications are prepared by licensed pharmacies to meet individual patient needs... Brand-name medications go through FDA approval and standardized manufacturing; compounded versions are not FDA-approved as finished products, but they use FDA-compliant ingredients and are prepared under regulated conditions."

This statement reflects Oak's description of their program. Patients should understand that differences in formulation, quality control processes, salt forms used, dosing accuracy, and clinical outcomes may exist between compounded products and FDA-approved versions - and that those differences have not been uniformly studied.

The FDA has documented specific concerns about compounded GLP-1 products: dosing variability, adverse event reports, improper storage during shipping, and the use of non-equivalent semaglutide salt forms - including semaglutide sodium and semaglutide acetate - that differ from the active ingredient in FDA-approved products. These concerns do not mean every compounded product from every pharmacy carries the same risk. They mean the variance in quality across the compounding market is real, and the questions you ask before starting treatment matter.

Before enrolling in any program, ask specifically: Which pharmacy will compound my medication? What accreditations does that pharmacy hold (NABP, PCAB, ACHC)? What salt form of semaglutide or tirzepatide do they use? Does each batch undergo third-party quality testing, and can they provide a Certificate of Analysis? Readers should rely on official FDA guidance, their licensed healthcare provider, and verified pharmacy information - not platform marketing - when evaluating any GLP-1 program.

View the current Oak program offer (official Oak page)

The FDA's March 2026 Enforcement Action: What It Said, Who It Named, and What It Means for Patients Evaluating Oak

In March 2026, the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products. These warning letters were issued to specific named companies and do not apply universally to all telehealth platforms - but they establish the compliance standard the FDA is actively enforcing across the category right now.

The two violations the FDA cited most frequently across those 30 companies were: first, making claims that implied compounded medications were the same as or equivalent to FDA-approved products; and second, advertising compounded drugs under the telehealth company's own branding without clearly disclosing that the telehealth firm was not the compounder. FDA Commissioner Marty Makary stated at the time: "Compounded drugs can be important for overcoming shortages or meeting unique patient needs - but compounders should not try to compound drugs in a way that circumvents FDA's approval process."

Based on publicly available FDA information, Oak Longevity was not among the 30 companies named in this campaign. However, the enforcement action defines the standard patients should use to evaluate any platform. The right questions to ask Oak - or any platform - in light of these letters: Does the platform clearly and consistently distinguish compounded products from FDA-approved ones in its current marketing? Does it identify its pharmacy partners by name and accreditation? Does the clinical process involve genuine individualized review, not just a checkbox intake?

This article's review of Oak's publicly available Terms of Use found that Oak does maintain the platform-clinician-pharmacy separation that the FDA's enforcement standard requires. Readers should verify Oak's current marketing language and confirm pharmacy partner details directly with Oak before enrolling, as marketing materials can change independently of terms of use documents.

Regulatory interpretations can change, and enforcement priorities may shift over time - which is exactly why direct verification with the provider, the prescribing clinician, and the dispensing pharmacy is essential before making any treatment decision. This section is based on publicly available FDA information and does not constitute legal advice.

A Note on Pricing Stability in the Current Environment

Pricing in the compounded GLP-1 space is less stable in April 2026 than it was twelve months ago. According to industry reporting, multiple platforms have raised prices or changed their program structures as pharmacy supply chains have narrowed under increased regulatory pressure. The prices referenced in this article reflect Oak's published website as of April 2026. In this category, "current pricing" means exactly that - current at the moment of verification. Confirm directly before enrolling.

Oak GLP-1 Pricing in April 2026: What the Website Shows, and What to Verify

Pricing transparency is one of the most important things to evaluate in this space, because the gap between advertised entry pricing and actual total program cost is where most patient frustration originates. Here is what Oak's website currently shows, with the right context around each number.

According to Oak's official website, promotional pricing is currently advertised as:

Compounded Semaglutide - as low as $130 per month
Compounded Tirzepatide - as low as $199 per month

Oak is also advertising a first-month promotion of $50 off using code OAKNEW50. The website advertises "one price, all dosages" and references free shipping on all orders.

Oak's website also states "Up to 50% cheaper than competitors." This is Oak's own marketing claim. Independent price comparisons of specific platforms were not conducted for this article. What is verifiable: Oak's published entry pricing of $130 for semaglutide and $199 for tirzepatide lands within the lower advertised range among comparable telehealth offerings currently on the market, based on publicly available competitor pricing. Total program cost will depend on your dosage progression as you titrate up, refill timing, and any additional services. Confirm the full cost picture with Oak directly before enrolling - entry pricing and maintenance pricing are frequently different.

One important detail from Oak's Terms of Use that the homepage advertising does not emphasize: "most of these prescriptions are configured as a subscription that will renew on a recurring basis." The homepage advertises "no subscriptions." The Terms of Use govern. Review the checkout terms, refill schedule, cancellation window, and renewal structure carefully before submitting payment.

Per Oak's Terms of Use: Medicare and Medicaid do not cover Oak's products and services. Oak does not work with commercial health insurance plans. All costs are cash-pay. HSA and FSA eligibility varies by state and individual plan - Oak's Terms state this is the client's responsibility to confirm with their plan administrator.

All pricing information was based on Oak's publicly available website as of April 2026 and is subject to change without notice. Always verify current pricing, promotional terms, and eligibility on the official Oak page before enrolling.

View the current Oak program offer (official Oak page)

How the Oak Process Actually Works: A Step-by-Step Breakdown

Oak's website describes a three-step process. Here is what each step involves based on Oak's published information and Terms of Use - including the details the marketing copy doesn't highlight.

Step 1: Complete a health intake form. You answer questions about your health goals, medical history, current medications, and relevant conditions online. No video call is required for most users. According to Oak's Terms of Use, the information you provide is the primary basis for the provider physician's clinical evaluation - and Oak explicitly requires all answers to be "true, factual, exact, current and thorough." Providing inaccurate information is your liability under their terms, not Oak's. Take the intake seriously.

Step 2: A licensed provider reviews your case. An independent physician or nurse practitioner contracted through Oak reviews your intake and determines whether treatment is clinically appropriate. Oak states this review can happen within hours. If the provider determines you are not a candidate for GLP-1 therapy, no prescription will be issued - that determination belongs entirely to the clinician, not to Oak's platform.

Step 3: Medication ships to your door. If a prescription is approved, a licensed partner pharmacy prepares and ships your medication to the address on your account. Shipping is free according to Oak's website. Oak's Terms of Use state that once a prescription is packed and within 48 hours of shipment, no returns are accepted and no refunds are issued for shipped medications. Understand this before you enroll.

Who Oak GLP-1 Is and Is Not a Good Fit For

Oak's website describes its program as best suited for adults who are ready to make a real change with licensed physician guidance. The site is also upfront about who may not be a good fit - and that transparency is worth taking seriously before you fill out an intake form anywhere.

Per Oak's own website, the program may not be appropriate if you are under 18 years old, if you are currently pregnant or nursing, or if your BMI is under 22 with no prior comorbidities.

Oak's Terms of Use also list health conditions that require you to stop medication immediately and consult a provider if they develop or change during treatment. These include, but are not limited to: heart attack or heart disease, stroke, cancer diagnosis, liver disease, DVT or clotting disorders, Graves' Disease, active cardiac arrhythmias, Addison's Disease, acute myocarditis, neck or thyroid swelling, multiple endocrine neoplasia, gastroparesis, pancreatitis, proliferative diabetic retinopathy, and renal failure requiring hemodialysis. This list is Oak's own terms - it is not exhaustive. If any of these conditions apply to you, discuss them directly with a licensed clinician who knows your full medical history before starting any GLP-1 program.

Oak May Be Worth Evaluating If You:

Need a lower-cost cash-pay entry point to compounded GLP-1 therapy. Oak's published pricing of $130 for semaglutide and $199 for tirzepatide is within the lower advertised range in this category. If brand-name costs are prohibitive and you understand what compounded means - and doesn't mean - this price point may be worth reviewing directly.

Prefer a fully digital process with no clinic visits required. Oak's intake is online, and the company states no video call is required for most users. If remote access and convenience are priorities, this model is structured around that.

Have had difficulty accessing GLP-1 prescriptions through traditional channels. For people who've encountered long waits, out-of-pocket costs, or limited local access, telehealth provides a different pathway - though it is not a substitute for comprehensive in-person care when your health situation requires it.

Other Options May Be a Better Fit If You:

Want or require an FDA-approved finished drug product. Compounded medications have not undergone FDA review as finished products. If you want Wegovy, Zepbound, or another FDA-approved GLP-1 with standardized manufacturing, dosing, and quality controls, that requires a different path - either through traditional prescribers or platforms offering branded options.

Have a complex medical history that warrants close clinical oversight. Asynchronous telehealth review may not provide the depth of evaluation some cases require. In-person care with a provider who knows your full history may be more appropriate.

Are depending on insurance coverage to offset medication costs. Oak operates entirely outside commercial insurance. If your plan may cover GLP-1 medications, that path requires a different provider entirely.

Eight Questions to Ask Before You Enroll Anywhere in 2026

These questions apply to Oak and to every other compounded GLP-1 telehealth platform. The answers matter more right now than they did a year ago.

1. Which pharmacy will compound my medication, and what are that pharmacy's current accreditations - NABP, PCAB, or ACHC?

2. What salt form of semaglutide or tirzepatide does the pharmacy use?

3. Does each batch undergo independent third-party quality testing, and can I receive a Certificate of Analysis?

4. How does the platform handle dose adjustments, side effects, and ongoing clinical support after the initial prescription?

5. What is the exact cancellation process, timeline, and refund policy for shipped medications?

6. Does my starting price hold at higher doses, or does pricing increase as I titrate up?

7. In which states is the platform currently operating and dispensing, and has that changed recently?

8. Has this platform received any FDA or FTC correspondence in the past twelve months?

Your answers to these questions determine the quality and risk profile of any program you choose - not the advertised entry price.

How to Get Started With Oak

According to Oak's website, the process begins with a short online health form. No video call is required for most users. Once intake is complete, a licensed provider reviews the information and determines whether treatment is appropriate. Oak states approvals can happen within hours of intake.

If a prescription is issued, medication ships directly to your address with free shipping and tracking, according to Oak's website. Specific shipping timelines should be confirmed with Oak directly, as they depend on pharmacy availability and your location.

For questions before or during enrollment, Oak's contact information per their official website:

Phone: 435-244-7757
Email: care@oaklovesyou.com
Website: oaklovesyou.com

View the current Oak program offer (official Oak page)

Final Verdict: Is Oak GLP-1 Legit - and Is It the Right Choice Right Now?

Oak Longevity is a telehealth platform with a published Terms of Use, a named corporate entity (Oak Longevity Holdings Corp.), listed contact information, an identified medical group structure (NVP Medical Group, P.A.), and a publicly available legal framework a prospective patient can read before committing. It is not a faceless operation. There is verifiable infrastructure to examine.

The case for Oak in April 2026: If you're looking for a lower-cost, fully digital entry point to compounded GLP-1 therapy, understand what compounded means and doesn't mean, and have verified that the program fits your health profile and state eligibility, Oak's pricing and process are worth evaluating directly. The no-video-call intake, free shipping, and same-day review claim are practical advantages for people who value a streamlined remote experience.

What to weigh carefully: Compounded medications are not FDA-approved finished drug products. The regulatory environment for compounded GLP-1s is more actively enforced in April 2026 than it has been at any prior point. Oak's Terms of Use describe a recurring subscription structure that its homepage marketing doesn't emphasize - the Terms govern. No returns are accepted once medication ships. Prescription approval is never guaranteed. And the pricing landscape in this category is less stable than it was a year ago - verify before you commit.

On Oak's standing relative to the FDA's March 2026 enforcement action: Based on publicly available FDA information, Oak was not among the 30 companies named in that campaign. Oak's Terms of Use do maintain the platform-clinician-pharmacy separation that the FDA's enforcement standard requires. That is meaningful context - but it is not a substitute for verifying Oak's current pharmacy partners, their accreditation status, and their current regulatory standing directly.

Important Note: The compounded GLP-1 space has been under significant and growing regulatory scrutiny throughout 2025 and 2026. Patients should review the most current information about any telehealth platform's pharmacy standing, compliance status, and medication availability before proceeding. Regulatory interpretations can change and enforcement priorities may shift - direct verification with the provider and pharmacy before making any treatment decision is not optional. It is necessary.

The final judgment belongs to you - ideally made in conversation with a licensed healthcare provider who knows your medical history, after you have verified Oak's current program details directly.

View the current Oak program offer (official Oak page)

Frequently Asked Questions

Is compounded semaglutide still available in 2026?
Yes, but the landscape is narrower than it was in 2024. 503A patient-specific compounding by licensed pharmacies remains a legal pathway when a patient's medical needs cannot be met by a commercially available FDA-approved drug. The broad 503B outsourcing-facility compounding that drove large-scale availability in 2023-2024 has faced significantly tighter enforcement since early 2025. Verify any platform's current pharmacy arrangements and regulatory standing before enrolling.

Did the FDA shut down compounded GLP-1 programs?
No. The FDA has not issued a blanket prohibition on compounded GLP-1 medications. What the FDA did was issue warning letters to 30 specific telehealth companies for misleading marketing practices, and it has narrowed enforcement against 503B bulk compounding as the semaglutide shortage status changed. Patient-specific 503A compounding through licensed pharmacies, with a valid individual prescription, remains permissible under current FDA guidance in defined circumstances. The regulatory picture is narrower and more actively enforced - not closed.

What happened to GLP-1 telehealth companies after the FDA warning letters?
Companies named in the March 2026 warning letters were required to address specific marketing violations. Some have modified their website language; others have changed their program structure. Multiple platforms across the space - named and unnamed in the campaign - have adjusted pricing upward or changed pharmacy partners as the enforcement environment has tightened. This is why verifying a platform's current status directly matters more in April 2026 than it did twelve months ago.

How do I verify a GLP-1 telehealth platform is still compliant right now?
Ask the platform directly: which pharmacy compounds your medication, what that pharmacy's current accreditations are (NABP, PCAB, ACHC), whether each batch is third-party tested and you can receive a Certificate of Analysis, and whether the platform has received any FDA or FTC correspondence recently. Check the FDA's warning letter database at fda.gov for the platform's name. Verify the compounding pharmacy's license through your state board of pharmacy. LegitScript certification - held by some platforms - provides an additional independent verification layer.

Is Oak Longevity legit?
Oak Longevity is a telehealth platform with published Terms of Use, a named corporate entity, listed contact information, and contracted medical providers operating through identified U.S.-based medical professional corporations. Per Oak's own Terms, the platform does not provide medical services - licensed independent providers do. Oak was not named in the FDA's March 2026 warning letter campaign based on publicly available FDA information. Whether it is the right fit for your situation depends on your health profile, your understanding of compounded medications, your state's eligibility, and verification of Oak's current pharmacy partners and compliance status. Review Oak's terms directly and discuss with your physician.

Is Oak the same as Ozempic or generic semaglutide?
No. Oak's program uses compounded semaglutide and tirzepatide - not brand-name FDA-approved medications. There is no FDA-approved generic semaglutide as of April 2026. Compounded semaglutide is not a generic. It is a compounded preparation made by a licensed pharmacy under 503A or 503B regulations, using an active pharmaceutical ingredient intended to correspond to the active ingredient in branded products. The regulatory and quality standard is different. The two are not interchangeable terms.

Does Oak take insurance?
No. Per Oak's Terms of Use, Medicare and Medicaid do not cover Oak's products or services, and Oak does not work with commercial health insurance plans. All costs are cash-pay. HSA and FSA eligibility varies by individual plan - Oak's Terms indicate this is the client's responsibility to verify with their plan administrator before submitting payment.

Can I cancel my Oak subscription?
According to Oak's Terms of Use, you can cancel by logging into your Oak account and canceling your subscription or closing your account. Oak states cancellation aims to take effect within 24 hours of your action. Any refills already packaged or within 48 hours of shipment will be sent before cancellation takes effect, and no refunds are issued for shipped medications. Know this before you enroll - not after your first refill processes.

What states does Oak operate in?
Oak's Terms of Use state it provides services in 45 U.S. states, with certain states excluded based on local law. Verify your state's current eligibility directly on the Oak website before completing your intake form - operating states can change as state regulatory environments shift.

Disclaimers

Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The descriptions of potential benefits are not guarantees and are not a substitute for an individualized medical evaluation. Oak GLP-1 medications are compounded prescription medications that require evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. Compounded GLP-1 medications are not substitutes for prescribed medical treatment through your primary care provider. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting any compounded GLP-1 program. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval.

Compounded Medication Notice: Oak's GLP-1 medications are compounded prescription medications prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They are prepared using active ingredients sourced from FDA-registered facilities under the direction of a prescribing clinician. Compounded medications are not the same as FDA-approved brand-name GLP-1 medications such as Ozempic, Wegovy, Mounjaro, or Zepbound.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, consistency of use, genetic factors, current medications, adherence to clinician recommendations, lifestyle factors, and other individual variables. Weight loss outcomes are not guaranteed. Oak's website references a weight loss calculator described as "based on real results from Oak patients" - any figures presented represent Oak's marketing estimates, not guarantees, and should not be interpreted as typical or predictable for any individual. Any customer experiences referenced by Oak or third-party review platforms should not be interpreted as typical results - individual outcomes will vary significantly.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from Oak's official website and Terms of Use.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were based on Oak's publicly available website as of April 2026 and are subject to change without notice. Pricing in the compounded GLP-1 category has been less stable than prior years due to evolving regulatory and supply chain pressures. Always verify current pricing, terms, and promotional availability directly on the official Oak website before enrolling.

Publisher Responsibility: The publisher of this article has made every effort to ensure accuracy at the time of publication based on publicly available information. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with Oak Longevity and their healthcare provider before making any decisions.

Insurance Coverage Note: Per Oak's Terms of Use, Oak does not accept commercial health insurance, Medicare, or Medicaid. Cash-pay is required for all products and services. HSA and FSA eligibility varies by plan - confirm with your plan administrator before submitting payment. Always confirm current benefits directly with your insurer before enrolling in any telehealth program.

Regulatory Note: This article references publicly available FDA guidance and the FDA's March 2026 warning letter campaign targeting 30 telehealth companies. This information is provided for educational context only and does not constitute legal or regulatory advice. The regulatory status of any specific prescription, pharmacy, formulation, or state-level offering should be verified directly with the relevant parties before making any treatment decision.

SOURCE: Oak

Source: Oak